RankAlpha logo
Back to Rankings

EXEL

ExelixisC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The Q1 print showed continued cabozantinib franchise growth, with net product revenue up year over year on volume, while management kept 2026 guidance unchanged and reiterated a dense zanzalintinib milestone calendar. Post-earnings target increases from Morgan Stanley, Stifel, TD Cowen, and H.C.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Cabozantinib still accounts for the majority of revenue, leaving the story exposed to single-franchise concentration risk [#10-Q-2026-05-05].
Momentum
51
Value
65
Sentiment
33
Setup hits (3d)
— · Net —
AI TargetsBase $48.00 · Bull $56.00 · Bear $39.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $51.19
Why
Momentum51 · Δ7d -18.2
Value65 · Δ7d -0.0
Sentiment33 · Δ7d -1.7
So what
Balanced signals. Wait for confirmation before sizing up.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Value · See fundamentals
Momentum
51
26% active weight
Current posture
7d trendFlat
Δ7d
-18.2
Δ21d
-31.2
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
33
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.7
Δ21d
-3.4
Why this grade

Composite grade C. Momentum 51.3 / Value 65.2 / Sentiment 33.2

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$14.06B
Beta
0.42
Shares Out
251.36M
P/E (TTM)
17.9
P/S (TTM)
4.97
P/FCF (TTM)
14.58
Rev YoY
+10.0%
EPS YoY
+42.1%
Gross Margin
+96.4%
Op Margin
+35.0%
Net Debt
-$858.17M
Current Ratio
3.26
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology